Nonmalignant Hematologic Disorders

Expert faculty review and share their insights and perspectives on key findings in nonmalignant hematologic disorders presented at the 2021 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2021: Nonmalignant
    Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2021
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 01, 2022

    Expires: February 28, 2023

Activities

SOLACE-kids
SOLACE-kids: Phase II Study of Crizanlizumab in Adolescents With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

AREG: Monitoring in aGVHD
Amphiregulin as a Monitoring Biomarker for Patients With Acute GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

ATLAS-A/B
ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Iptacopan for PNH
Phase II Study of Iptacopan Monotherapy for Paroxysmal Nocturnal Hemoglobinuria: A 12-Mo Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

uhCG/EGF for aGVHD
Phase II Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-threatening Acute GVHD
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Abatacept for GVHD
Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

Etavopivat in SCD
Exploratory Analyses From a Phase I Study of Etavopivat in Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

Mitapivat for SCD
Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

ATLAS-INH: Fitusiran for Hemophilia A/B
ATLAS-INH: Phase III Trial of Fitusiran Prophylaxis in Patients With Hemophilia A or B With Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2021

Expires: December 20, 2022

Axatilimab in cGVHD
Phase I/II Study of Anti‒CSF-1R Antibody Axatilimab in Heavily Pretreated Chronic Graft-vs-Host Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

Faculty

cover img faculity

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

cover img faculity

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

cover img faculity

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation